What Big Pharma Must Learn From Unicorns in 2021

The concept of unicorn start-up is not yet a frequent case in pharma, but it already haunts so many minds in the industry. Navigating through complex issues to create win-win situations ad-hoc is something that could help established pharmas manage their own, very different issues.

In fact, these companies just cracked the code to comply with the success measures, and it is a secret to no one that it is agility. They know that nothing kills a good idea faster than internal silos and unnecessary complexities.

The path of unicorns is for ambitious ones, but quite possibly right now, it is the time for pharma to follow this path and take advantage of their valuable experience.

CBInsights say the number of healthcare unicorns has grown, and 55% of total exits have happened since 2020. The pandemic has indeed increased the focus and influx of investments in pharmaceuticals, thereby making it an attractive open for the implementation of the most ambitious and innovative ideas.

In the end, many also realized that digital technologies are shaping the healthcare sector of the future, and, as a result, they choose the most daring digital initiatives to invest in.

Discover the most valuable lessons that Big Pharmas can learn from unicorn start-ups at our free partner webinar with Impatient health. During the session “What Big Pharma Must Learn From Unicorns in 2021”, July 2, 9:00 AM EDT, you will hear about: 

• How do the most successful start-ups build true learning organizations and justify their sky-high valuations?
• What would happen if pharma’s great brand teams had the unicorn mindset
• What it really takes to unlock the potential of our industry in a post-pandemic world.